Home Patent Forecast® Sectors Log In   Contact  
How it works Patent Forecast® Sectors Insights
Enjoy your FREE PREVIEW which shows only 2022 data and 25 documents. Contact Patent Forecast for full access.        


Read More News and Insights

THCV to Alleviate Cancer Therapy Side-effects

Z-ARCHIVE-Cannabis Patent Forecast®

July 2, 2020

A remarkable invention has surfaced this week disclosed in issued US patent 10,688,191 for a chemically linked cannabinoid and chemotherapy agent. As the chemotherapy agent breaches the blood-brain barrier, the linked cannabinoid is able to act on the endocannabinoid receptors to alleviate some of the side effects of the chemotherapy agent. 

Patent ‘191 specifically mentions the use of tetrahydrocannabivarin (THCV) and Carmustine as the cannabinoid and chemotherapy agent, respectively. THCV is a homologue molecule of THC and produces different side effects from THC. Cannabis site Leafly states that the common effects of THCV include appetite suppressant, stimulating bone growth as well as possibly helping with Alzheimer’s disease, diabetes, and reducing panic attacks. 

HR BIOMED LLC, a Goshen, OH based company, is the assignee for patent ‘191 and appears to be operating in stealth mode at the moment. Check out Magic Number’s Cannabis Patent Forecast® to stay up to date with the cannabis industry’s vast set of intellectual property. 

child sitting on bed

Relevant Patent Documents

Patent US10688191  

Article Source Link


Read more like this in News This Week!   or   Share this link with your connections!